AAAAAA
Results:
1-10
|
Results: 10
Authors:
Kenakin, T
Citation: T. Kenakin, A message from Terry Kenakin, RECEPT CHAN, 7(4), 2001, pp. 247-248
Authors:
Kenakin, T
Citation: T. Kenakin, Inverse, protean, and ligand-selective agonism: matters of receptor conformation, FASEB J, 15(3), 2001, pp. 598-611
Authors:
Kenakin, T
Citation: T. Kenakin, The pharmacologic consequences of modeling synoptic receptor systems, PHARM TOXIC, 2001, pp. 1-20
Authors:
Corsi, M
Kenakin, T
Citation: M. Corsi et T. Kenakin, The relative importance of the time-course of receptor occupancy and response decay on apparent antagonist potency in dynamic assays, J AUT PHARM, 20(4), 2000, pp. 221-227
Authors:
Watson, C
Chen, G
Irving, P
Way, J
Chen, WJ
Kenakin, T
Citation: C. Watson et al., The use of stimulus-biased assay systems to detect agonist-specific receptor active states: Implications for the trafficking of receptor stimulus by agonists, MOLEC PHARM, 58(6), 2000, pp. 1230-1238
Authors:
Chen, G
Way, J
Armour, S
Watson, C
Queen, K
Jayawickreme, CK
Chen, WJ
Kenakin, T
Citation: G. Chen et al., Use of constitutive G protein-coupled receptor activity for drug discovery, MOLEC PHARM, 57(1), 2000, pp. 125-134
Authors:
Kenakin, T
Citation: T. Kenakin, Efficacy in drug receptor theory: outdated concept or under-valued tool?, TRENDS PHAR, 20(10), 1999, pp. 400-405
Authors:
Kenakin, T
Citation: T. Kenakin, The measurement of efficacy in the drug discovery agonist selection process, J PHARM TOX, 42(4), 1999, pp. 177-187
Authors:
Chen, G
Jayawickreme, C
Way, J
Armour, S
Queen, K
Watson, C
Ignar, D
Chen, WJ
Kenakin, T
Citation: G. Chen et al., Constitutive receptor systems for drug discovery, J PHARM TOX, 42(4), 1999, pp. 199-206
Authors:
Armour, SL
Foord, S
Kenakin, T
Chen, WJ
Citation: Sl. Armour et al., Pharmacological characterization of receptor-activity-modifying proteins (RAMPs) and the human calcitonin receptor, J PHARM TOX, 42(4), 1999, pp. 217-224
Risultati:
1-10
|